This CPB has been revised to state that (i) plasmapheresis (PP), plasma exchange (PE), or therapeutic apheresis is considered medically necessary for anti-neutrophil cytoplasmic antibody-associated vasculitis, and recurrence of focal and segmental glomerulosclerosis in the kidney allograft; and (ii) PP/PE or therapeutic apheresis is considered experimental and investigational for anti-MAG neuropathy, and stiff-person syndrome.